United Kingdom

People: Aravive Inc (ARAV.OQ)

ARAV.OQ on NASDAQ Stock Exchange Global Select Market

6:40pm BST
Change (% chg)

$0.10 (+1.72%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Shepard, Jay 

Mr. Jay P. Shepard is the President, Chief Executive Officer, Director of Versartis, Inc. Mr. Jay P. Shepard has served as a member and the chairman of our board of directors since December 2013. Mr. Shepard is currently an Executive Partner at Sofinnova Ventures, or Sofinnova, a venture capital firm focused on the healthcare industry, which he joined as an Executive in Residence in 2008. Mr. Shepard previously served as President and Chief Executive Officer and was a member of the board of directors of NextWave Pharmaceuticals, Inc., a specialty pharmaceutical company developing and commercializing unique pediatric products utilizing proprietary drug delivery technology that was acquired by Pfizer in November 2012, from January 2010 to November 2012. From December 2005 to October 2007, Mr. Shepard served as President and Chief Executive Officer and a member of the board of directors of Ilypsa Inc., a biopharmaceutical company pioneering novel non-absorbed polymeric drugs for renal and metabolic disorders that was acquired by Amgen in July 2007. Mr. Shepard has served on the boards of directors of numerous public and private companies, including Ilypsa, Relypsa, Inc. and Intermune, Inc., and currently serves on the board of directors of Bullet Biotechnology, Inc., Marinus Pharmaceuticals, Inc., and Durect Corporation. Mr. Shepard holds B.S. in Business Administration from the University of Arizona.

Basic Compensation

Total Annual Compensation, USD 541,298
Restricted Stock Award, USD 2,037,360
Long-Term Incentive Plans, USD --
All Other, USD 1,492,140
Fiscal Year Total, USD 4,070,800

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --